Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases

•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered. A uniform treatment strategy for patients suffering fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical colorectal cancer 2021-12, Vol.20 (4), p.e263-e272
Hauptverfasser: Hellingman, Tessa, Kuiper, Babette I., Buffart, Laurien M., Meijerink, Martijn R., Versteeg, Kathelijn S., Swijnenburg, Rutger-Jan, van Delden, Otto M., Haasbeek, Cornelis J.A., de Vries, Jan J.J., van Waesberghe, Jan Hein T.M., Zonderhuis, Barbara M., van der Vliet, Hans J., Kazemier, Geert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e272
container_issue 4
container_start_page e263
container_title Clinical colorectal cancer
container_volume 20
creator Hellingman, Tessa
Kuiper, Babette I.
Buffart, Laurien M.
Meijerink, Martijn R.
Versteeg, Kathelijn S.
Swijnenburg, Rutger-Jan
van Delden, Otto M.
Haasbeek, Cornelis J.A.
de Vries, Jan J.J.
van Waesberghe, Jan Hein T.M.
Zonderhuis, Barbara M.
van der Vliet, Hans J.
Kazemier, Geert
description •Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered. A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM. Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.
doi_str_mv 10.1016/j.clcc.2021.07.007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2567987585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1533002821000724</els_id><sourcerecordid>2567987585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</originalsourceid><addsrcrecordid>eNp9kE9r3DAQxUVJaf40XyCHomMudkeSZXkhl2ZJmsKWliY5C0UeFy22tZHshUA_fMdsmmNBSG-G9x7ox9iFgFKAqD9vS997X0qQogRTAph37ESsVFNAbaoj0lqpAkA2x-w05y2pWgnxgR2rqqqlFOKE_bmf0z7sXc-vccQuTDx2_Bfu0E18Ez3tHxLpAceJh5H_dFMgmfn93HWYwvib36Y48BuX-hfK-TklHD0uLevYx4R-oo61o13im7Cn-ztOLtPB_JG971yf8fz1PWOPtzcP67ti8-Prt_WXTeErgKmovdIOmlWraZYKUBgUNBunwDVVJVothfZOSxSuAgNSa9fUrvatwgqFOmOXh95dis8z5skOIXvsezdinLOVujarxuhGk1UerD7FnBN2dpfC4NKLFWAX6nZrF-p2oW7BWKJOoU-v_fPTgO1b5B9mMlwdDEi_3AdMNvuwcGrDQsi2Mfyv_y9x4JMT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2567987585</pqid></control><display><type>article</type><title>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hellingman, Tessa ; Kuiper, Babette I. ; Buffart, Laurien M. ; Meijerink, Martijn R. ; Versteeg, Kathelijn S. ; Swijnenburg, Rutger-Jan ; van Delden, Otto M. ; Haasbeek, Cornelis J.A. ; de Vries, Jan J.J. ; van Waesberghe, Jan Hein T.M. ; Zonderhuis, Barbara M. ; van der Vliet, Hans J. ; Kazemier, Geert</creator><creatorcontrib>Hellingman, Tessa ; Kuiper, Babette I. ; Buffart, Laurien M. ; Meijerink, Martijn R. ; Versteeg, Kathelijn S. ; Swijnenburg, Rutger-Jan ; van Delden, Otto M. ; Haasbeek, Cornelis J.A. ; de Vries, Jan J.J. ; van Waesberghe, Jan Hein T.M. ; Zonderhuis, Barbara M. ; van der Vliet, Hans J. ; Kazemier, Geert</creatorcontrib><description>•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered. A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM. Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.</description><identifier>ISSN: 1533-0028</identifier><identifier>EISSN: 1938-0674</identifier><identifier>DOI: 10.1016/j.clcc.2021.07.007</identifier><identifier>PMID: 34462211</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Ablation ; Colorectal Neoplasms - surgery ; Hepatectomy ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - surgery ; Neoplasm Recurrence, Local - therapy ; Retrospective Studies ; Survival analysis ; Systemic therapy ; Treatment strategy</subject><ispartof>Clinical colorectal cancer, 2021-12, Vol.20 (4), p.e263-e272</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</citedby><cites>FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</cites><orcidid>0000-0002-5322-3561 ; 0000-0002-7596-1012 ; 0000-0001-6786-4215 ; 0000-0003-3861-617X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clcc.2021.07.007$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34462211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hellingman, Tessa</creatorcontrib><creatorcontrib>Kuiper, Babette I.</creatorcontrib><creatorcontrib>Buffart, Laurien M.</creatorcontrib><creatorcontrib>Meijerink, Martijn R.</creatorcontrib><creatorcontrib>Versteeg, Kathelijn S.</creatorcontrib><creatorcontrib>Swijnenburg, Rutger-Jan</creatorcontrib><creatorcontrib>van Delden, Otto M.</creatorcontrib><creatorcontrib>Haasbeek, Cornelis J.A.</creatorcontrib><creatorcontrib>de Vries, Jan J.J.</creatorcontrib><creatorcontrib>van Waesberghe, Jan Hein T.M.</creatorcontrib><creatorcontrib>Zonderhuis, Barbara M.</creatorcontrib><creatorcontrib>van der Vliet, Hans J.</creatorcontrib><creatorcontrib>Kazemier, Geert</creatorcontrib><title>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</title><title>Clinical colorectal cancer</title><addtitle>Clin Colorectal Cancer</addtitle><description>•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered. A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM. Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.</description><subject>Ablation</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Hepatectomy</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Retrospective Studies</subject><subject>Survival analysis</subject><subject>Systemic therapy</subject><subject>Treatment strategy</subject><issn>1533-0028</issn><issn>1938-0674</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9r3DAQxUVJaf40XyCHomMudkeSZXkhl2ZJmsKWliY5C0UeFy22tZHshUA_fMdsmmNBSG-G9x7ox9iFgFKAqD9vS997X0qQogRTAph37ESsVFNAbaoj0lqpAkA2x-w05y2pWgnxgR2rqqqlFOKE_bmf0z7sXc-vccQuTDx2_Bfu0E18Ez3tHxLpAceJh5H_dFMgmfn93HWYwvib36Y48BuX-hfK-TklHD0uLevYx4R-oo61o13im7Cn-ztOLtPB_JG971yf8fz1PWOPtzcP67ti8-Prt_WXTeErgKmovdIOmlWraZYKUBgUNBunwDVVJVothfZOSxSuAgNSa9fUrvatwgqFOmOXh95dis8z5skOIXvsezdinLOVujarxuhGk1UerD7FnBN2dpfC4NKLFWAX6nZrF-p2oW7BWKJOoU-v_fPTgO1b5B9mMlwdDEi_3AdMNvuwcGrDQsi2Mfyv_y9x4JMT</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Hellingman, Tessa</creator><creator>Kuiper, Babette I.</creator><creator>Buffart, Laurien M.</creator><creator>Meijerink, Martijn R.</creator><creator>Versteeg, Kathelijn S.</creator><creator>Swijnenburg, Rutger-Jan</creator><creator>van Delden, Otto M.</creator><creator>Haasbeek, Cornelis J.A.</creator><creator>de Vries, Jan J.J.</creator><creator>van Waesberghe, Jan Hein T.M.</creator><creator>Zonderhuis, Barbara M.</creator><creator>van der Vliet, Hans J.</creator><creator>Kazemier, Geert</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5322-3561</orcidid><orcidid>https://orcid.org/0000-0002-7596-1012</orcidid><orcidid>https://orcid.org/0000-0001-6786-4215</orcidid><orcidid>https://orcid.org/0000-0003-3861-617X</orcidid></search><sort><creationdate>202112</creationdate><title>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</title><author>Hellingman, Tessa ; Kuiper, Babette I. ; Buffart, Laurien M. ; Meijerink, Martijn R. ; Versteeg, Kathelijn S. ; Swijnenburg, Rutger-Jan ; van Delden, Otto M. ; Haasbeek, Cornelis J.A. ; de Vries, Jan J.J. ; van Waesberghe, Jan Hein T.M. ; Zonderhuis, Barbara M. ; van der Vliet, Hans J. ; Kazemier, Geert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Ablation</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Hepatectomy</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Retrospective Studies</topic><topic>Survival analysis</topic><topic>Systemic therapy</topic><topic>Treatment strategy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hellingman, Tessa</creatorcontrib><creatorcontrib>Kuiper, Babette I.</creatorcontrib><creatorcontrib>Buffart, Laurien M.</creatorcontrib><creatorcontrib>Meijerink, Martijn R.</creatorcontrib><creatorcontrib>Versteeg, Kathelijn S.</creatorcontrib><creatorcontrib>Swijnenburg, Rutger-Jan</creatorcontrib><creatorcontrib>van Delden, Otto M.</creatorcontrib><creatorcontrib>Haasbeek, Cornelis J.A.</creatorcontrib><creatorcontrib>de Vries, Jan J.J.</creatorcontrib><creatorcontrib>van Waesberghe, Jan Hein T.M.</creatorcontrib><creatorcontrib>Zonderhuis, Barbara M.</creatorcontrib><creatorcontrib>van der Vliet, Hans J.</creatorcontrib><creatorcontrib>Kazemier, Geert</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical colorectal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hellingman, Tessa</au><au>Kuiper, Babette I.</au><au>Buffart, Laurien M.</au><au>Meijerink, Martijn R.</au><au>Versteeg, Kathelijn S.</au><au>Swijnenburg, Rutger-Jan</au><au>van Delden, Otto M.</au><au>Haasbeek, Cornelis J.A.</au><au>de Vries, Jan J.J.</au><au>van Waesberghe, Jan Hein T.M.</au><au>Zonderhuis, Barbara M.</au><au>van der Vliet, Hans J.</au><au>Kazemier, Geert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</atitle><jtitle>Clinical colorectal cancer</jtitle><addtitle>Clin Colorectal Cancer</addtitle><date>2021-12</date><risdate>2021</risdate><volume>20</volume><issue>4</issue><spage>e263</spage><epage>e272</epage><pages>e263-e272</pages><issn>1533-0028</issn><eissn>1938-0674</eissn><abstract>•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered. A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM. Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses. A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021). Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM. Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34462211</pmid><doi>10.1016/j.clcc.2021.07.007</doi><orcidid>https://orcid.org/0000-0002-5322-3561</orcidid><orcidid>https://orcid.org/0000-0002-7596-1012</orcidid><orcidid>https://orcid.org/0000-0001-6786-4215</orcidid><orcidid>https://orcid.org/0000-0003-3861-617X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1533-0028
ispartof Clinical colorectal cancer, 2021-12, Vol.20 (4), p.e263-e272
issn 1533-0028
1938-0674
language eng
recordid cdi_proquest_miscellaneous_2567987585
source MEDLINE; Elsevier ScienceDirect Journals
subjects Ablation
Colorectal Neoplasms - surgery
Hepatectomy
Humans
Liver Neoplasms - drug therapy
Liver Neoplasms - surgery
Neoplasm Recurrence, Local - therapy
Retrospective Studies
Survival analysis
Systemic therapy
Treatment strategy
title Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Benefit%20of%20Repeat%20Local%20Treatment%20in%20Patients%20Suffering%20From%20Early%20Recurrence%20of%20Colorectal%20Cancer%20Liver%20Metastases&rft.jtitle=Clinical%20colorectal%20cancer&rft.au=Hellingman,%20Tessa&rft.date=2021-12&rft.volume=20&rft.issue=4&rft.spage=e263&rft.epage=e272&rft.pages=e263-e272&rft.issn=1533-0028&rft.eissn=1938-0674&rft_id=info:doi/10.1016/j.clcc.2021.07.007&rft_dat=%3Cproquest_cross%3E2567987585%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2567987585&rft_id=info:pmid/34462211&rft_els_id=S1533002821000724&rfr_iscdi=true